#1 Clinical Trials Search in Europe

[4-(Methyl-1H-Pyrazol-4-Yl)-Benzyl] (6[7-(3-Pyrrolidin-1-Yl-Propoxy)-Imidazo[1,2-A] Pyridin-3-Yl]-Pyrimidin-4-Yl]-Amine

This article discusses the ongoing clinical trials of IDRX-42, a novel drug being studied for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST). IDRX-42 is a highly selective small molecule tyrosine kinase inhibitor that shows potential in treating GIST patients who have progressed on or are ineligible for standard therapies. The trials aim to evaluate the safety, efficacy, and optimal dosing of IDRX-42 in various patient populations with GIST.

Table of Contents

Introduction to IDRX-42

IDRX-42 is a new medication being developed for the treatment of gastrointestinal stromal tumors (GIST). It is currently undergoing clinical trials to evaluate its safety and effectiveness. IDRX-42 is also known by its chemical name [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL] (6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A] PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE[1].

What is Gastrointestinal Stromal Tumor (GIST)?

Gastrointestinal stromal tumor (GIST) is a type of cancer that develops in the digestive system, most commonly in the stomach or small intestine. These tumors start in special cells called interstitial cells of Cajal (ICC). GISTs can be metastatic (spread to other parts of the body) or unresectable (cannot be completely removed by surgery)[1].

How IDRX-42 Works

IDRX-42 is classified as a tyrosine kinase inhibitor. It is designed to be highly selective, meaning it targets specific proteins in cancer cells while minimizing effects on healthy cells. Tyrosine kinase inhibitors work by blocking signals that cancer cells need to grow and divide[1].

Current Clinical Trial of IDRX-42

A clinical trial is currently underway to study IDRX-42 in patients with GIST. This trial is called a “First-in-Human” (FIH) study, which means it’s the first time this drug is being tested in people. The study focuses on patients with GIST that is either metastatic or cannot be removed by surgery[1].

Who Can Participate in the Trial?

The trial is open to patients who meet certain criteria, including:

  • Age 18 or older
  • Confirmed diagnosis of metastatic or unresectable GIST
  • Have a specific genetic mutation in their tumor (KIT or certain PDGFRA mutations)
  • Have previously been treated with other GIST medications and experienced disease progression

There are also specific criteria for different parts of the study. For example, some patients may be eligible if they’ve only tried one previous treatment, while others may have tried several[1].

Objectives of the Clinical Trial

The main goals of this clinical trial are to:

  1. Determine the safe dose of IDRX-42
  2. Evaluate how well patients tolerate the drug
  3. Assess how effective IDRX-42 is in treating GIST
  4. Study how the drug behaves in the body (pharmacokinetics)

The researchers will measure things like the objective response rate (how many patients’ tumors shrink), duration of response (how long the tumors stay smaller), and progression-free survival (how long patients live without their cancer getting worse)[1].

Design of the Clinical Trial

The trial is divided into two main parts:

  1. Phase 1: This part will enroll about 66 patients and focus on finding the right dose of IDRX-42.
  2. Phase 1b: This part will enroll about 144 patients divided into four groups based on their previous treatments. It will further study the safety and effectiveness of IDRX-42[1].

Potential Benefits of IDRX-42

While it’s important to remember that IDRX-42 is still experimental, it could potentially offer several benefits for GIST patients:

  • A new treatment option for patients who have tried other medications without success
  • Possibly more targeted action against GIST cells, which could mean fewer side effects
  • Potential to slow down or stop the growth of GIST tumors
  • May be effective against GISTs with specific genetic mutations

As with any new treatment, the full benefits and risks of IDRX-42 will only be known after thorough clinical testing[1].

Aspect Details
Drug Name IDRX-42
Drug Type Highly selective small molecule tyrosine kinase inhibitor
Target Condition Metastatic and/or unresectable gastrointestinal stromal tumors (GIST)
Trial Phases Integrated Phase 1/1b
Main Objectives Determine safe dose, evaluate safety and efficacy
Patient Groups Various, including treatment-naïve and previously treated patients
Key Measurements Safety, pharmacokinetics, tumor response, survival rates
Administration Oral (tablets and capsules)

FAQ

  • What is IDRX-42? IDRX-42 is a new drug being tested for the treatment of gastrointestinal stromal tumors (GIST). It is a highly selective small molecule tyrosine kinase inhibitor, which means it targets specific proteins involved in cancer growth.
  • What type of cancer is being studied in these trials? The trials are focusing on gastrointestinal stromal tumors (GIST) that are metastatic (spread to other parts of the body) and/or unresectable (cannot be completely removed by surgery).
  • Who can participate in these clinical trials? Participants must be at least 18 years old (19 in Korea) with confirmed GIST. Different trial phases have specific requirements, such as having progressed on previous treatments like imatinib or sunitinib. Some cohorts include treatment-naïve patients or those who have tried multiple lines of therapy.
  • What are the main goals of these clinical trials? The main goals are to determine the safe and effective dose of IDRX-42, evaluate its safety and tolerability, assess how the body processes the drug (pharmacokinetics), and measure its effectiveness in treating GIST through various measures like tumor response and survival rates.
  • How is the effectiveness of IDRX-42 being measured? The effectiveness is being measured through several outcomes, including objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). These measurements help determine how well the tumors respond to the treatment and how long the benefits last.

Ongoing Clinical Trials on [4-(Methyl-1H-Pyrazol-4-Yl)-Benzyl] (6[7-(3-Pyrrolidin-1-Yl-Propoxy)-Imidazo[1,2-A] Pyridin-3-Yl]-Pyrimidin-4-Yl]-Amine

  • Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

Glossary

  • Gastrointestinal Stromal Tumor (GIST): A type of cancer that begins in special cells in the wall of the gastrointestinal tract, called interstitial cells of Cajal.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Unresectable: Unable to be completely removed by surgery.
  • Tyrosine Kinase Inhibitor: A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Dose-Limiting Toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.

References

  1. http://clinicaltrials.eu/trial/study-of-idrx-42-for-patients-with-metastatic-or-unresectable-gastrointestinal-stromal-tumors-gist/